Positive news from portfolio company Oxford BioTherapeutics – it has announced today that it has achieved another milestone with Boehringer Ingelheim for the progress of a second oncology drug candidate.
Interested in Building a portfolio of shares in the future of UK technology?
Choose an option below to request an information pack: